Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation

Canadian Journal of Cardiology

Volumn 14, Issue 5, 1998, Pages 695-702

  Teo, Koon K ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acetylsalicylic acid; Anticoagulants; Atrial fibrillation; Patterns of practice

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

ADULT; AGED; ARTICLE; CANADA; DRUG CONTRAINDICATION; FEMALE; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; RETROSPECTIVE STUDY; THROMBOEMBOLISM; VALVULAR HEART DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 2942533675     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306:1018-22.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147:1561-4
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
4. Phillips SJ, Whisnant JP, O'Fallon WM, Frye AL. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990;65:344-59.
5. Lake FR, Cullen KJ, de Klerk NH, McCall MG, Rosman DL. Atrial fibrillation and mortality in an elderly population. Aust NZ J Med 1989;19:321-6.
6. Montague T, Taylor L, Martin S, et al, for the CQIN Investigators. Can practice patterns and outcomes be successfully altered? Examples from cardiovascular medicine. Can J Cardiol 1995;11:487-92.
7. Levine HJ, Pauker SG, Eckman MH. Antithrombotic therapy in valvular heart disease. Chest 1995;108(4 Suppl):360S-70S.
8. Petersen P, Boysen G, Godtfredsen J, Andersen E, Andersen B. Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;i:175-9.
9. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
10. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55.
11. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation study: final results. Circulation 1991;84:527-39
12. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
13. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atnal fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
14. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-91.
15. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atnal fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
16. Canadian Cardiovascular Society Consensus Conference on Atrial Fibrillation. Can J Cardiol 1996;12(Suppl A):1A-61A.
17. McCrory EC, Matchar DB, Samsa G, Sanders LL, Pritchett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995;155:277-81.
18. Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991;151:1950-3.
19. Chang HJ, Bell JR, Deroo DB, Kirk JW, Wasson JH. Dartmouth Primary Care COOP Project. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med 1990;150:83-6.
20. Beyth RJ, Antani MR, Covinsky KE, et al. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med 1996;11:721-8.
21. Brodsky MA, Chun JG, Podrid PJ, et al. Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation. Arch Intern Med 1996;156:2553-62.
22. Hendry A, Campbell AM, Campbell G, Macdonald JB, Williams BO. Antithrombotic therapy prescribed for patients with non-rheumatic atrial fibrillation. Scott Med J 1994;39:110-1.
23. Bath PMW, Prasad A, Brown MM, MacGregor GA. Survey of use of anticoagulation in patients with atrial fibrillation. Br Med J 1993;307:1045.
24. Lip GYH, Tean KN, Dunn FG. Treatment of atrial fibrillation in a district general hospital. Br Heart J 1994;71:92-5.
25. Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med 1996;11:713-20.
26. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996;156:2537-41
27. Tsuyuki RT, Teo KK, Ikuta RM, Bay KS, Greenwood PV, Montague TJ. Mortality risk and patterns of practice in 2,070 patients with acute myocardial infarction, 1987-92. Relative importance of age, sex, and medical therapy. Chest 1994;105:1687-92.
28. Clinical Quality Improvement Network Investigators. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. The relative importance of age, sex and medical therapy. Arch Intern Med 1996;156:1669-73.
29. Lawson F, McAlister F, Ackman M, Ikuta R, Montague T. The utilization of antithrombotic prophylaxis for atrial fibrillation in a geriatric rehabilitation hospital. J Am Genatr Soc 1996;44:708-11.
30. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trial translate into effectiveness in practice? Arch Intern Med 1994;154:1945-53.
31. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
32. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of out-patient therapy. Am J Med 1989;87:144-52.
33. Van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy an analysis of risk factors. Arch Intern Med 1993;153:1557-62.
34. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med 1991;229:351-5.
35. Redwood M, Taylor C, Bain BJ, Matthews JH. The association of age with dosage requirement for warfarin. Age Ageing 1991;20:217-20.
36. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Ageing and the anticoagulant response to warfarin therapy. Ann Intern Med 1992;116:901-4.
37. Moulton AW, Singer DE, Haas JS. Risk factors for stroke in patients with non-rheumatic atrial fibrillation: a case-control study. Am J Med 1991;91:156-61
38. Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med 1994;154:1443-8.